Serum Levels of Alanine Aminotransferase Decrease With Age in Longitudinal Analysis

Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California 92093, USA.
Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association (Impact Factor: 7.9). 03/2012; 10(3):285-90.e1. DOI: 10.1016/j.cgh.2011.10.014
Source: PubMed


An increased level of alanine aminotransferase (ALT) is a marker of liver injury. The mean ALT level has been reported to decrease with age; we performed a longitudinal analysis to determine whether serum levels of ALT changes with age among community-dwelling, older adults in the US.
We analyzed clinical data from 2 cohorts of individuals who participated in the Rancho Bernardo Study, in Southern CA. The first cohort comprised 1073 community-dwelling participants (59% women); clinical data was collected from 1984-1987 and 1992-1997. The second cohort comprised 416 participants (64% women); data was collected from 1984-1987, 1992-1997, and 1997-1999. Demographic, metabolic covariates, ALT, bilirubin, and albumin were measured. Changes in individual ALT over time were examined in unadjusted and multivariable-adjusted linear and logistic regression analyses.
At the baseline visit, the patients' mean age was 65.7 years and body mass index was 24.9 kg/m(2). In cohort 1, the mean levels of ALT decreased with age by 10% (from 21 to 19 IU/L) between the time periods of 1984-1987 and 1992-1997 (P < .0001). In cohort 2, they decreased by 20% (from 20 to 16 IU/L) between the time periods of 1984-1987 and 1997-1999 (P < .0001). Categorically-defined increases in ALT also decreased with age (P < .0001). Results remained consistent in sex-specific analyses and after adjusting for metabolic syndrome components, alcohol use, bilirubin, and serum levels of albumin (P < .0001).
In a longitudinal analysis, we observed that levels of ALT decrease with age, independent of sex, metabolic factors, alcohol use, and results from commonly used liver function tests (bilirubin and albumin). When interpreting serum levels of ALT, physicians should consider patients' age especially in the elderly.

Download full-text


Available from: Ricki Bettencourt
  • Source
    • "As a covariate influencing ALT activity, the association between age and ALT activity has been described in previous studies 11-13. The impact of age on ALT fluctuation is not only present based on quantitative discrimination, but also on the diagnostic value in predicting all-cause and disease-specific mortality. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Measurement of serum alanine aminotransferase (ALT) is a common, readily available, and inexpensive laboratory assay in clinical practice. ALT activity is not only measured to detect liver disease, but also to monitor overall health. ALT activity is influenced by various factors, including viral hepatitis, alcohol consumption, and medication. Recently, the impact of metabolic abnormalities on ALT variation has raised concern due to the worldwide obesity epidemic. The normal ranges for ALT have been updated and validated considering the metabolic covariates in the various ethnic districts. The interaction between metabolic and demographic factors on ALT variation has also been discussed in previous studies. In addition, an extremely low ALT value might reflect the process of aging, and frailty in older adults has been raised as another clinically significant feature of this enzyme, to be followed with additional epidemiologic investigation. Timely updated, comprehensive, and systematic introduction of ALT activity is necessary to aid clinicians make better use of this enzyme.
    Preview · Article · Jun 2014 · International journal of medical sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: The subject of drug-induced liver injury (DILI) has been evolving for decades. While various guidance and other documents have been produced to help identify and manage DILI in the clinical trial setting, as well as the clinic, there are still many aspects of the process that remain incomplete. I have selected those aspects where guidance documents either do not cover all possible scenarios or where other recommendations are open to interpretation or where controversies still exist. The following discussion includes a number of these topics, including: when is it acceptable to continue development of a drug where hepatotoxicity is observed in animal models or other preclinical assessments? Should patients with underlying liver disease be routinely included in clinical trials? Are the current clinical and biochemical stopping rules for suspected DILI appropriate for all situations? Should we still be using fold elevations based on upper limits of normal or a subject’s own baseline values to assess the level of alanine aminotransferase or other liver-associated enzyme elevations? How can we best integrate the expanding fields of toxicogenomics, pharmacogenomics, metobolomics, proteomics and other new drug and host profiling into predicting DILI? Where do we stand with respect to a DILI biomarker to replace traditional liver associated enzymes? How do we improve upon the voluntary reporting system for adverse drug reactions? What are the most useful causality assessment methodologies to diagnose DILI and is it ever possible to exclude the drug in question? And how do we best determine and manage the competing benefits and risks of an agent causing DILI?
    No preview · Article · Jun 2013 · Pharmaceutical Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Higher fetuin-A levels have been linked to fatty liver disease (FLD), the most common cause of elevated alanine aminotransferase (ALT) levels, but associations between ALT and fetuin-A level have been inconsistent. The presence of the metabolic syndrome in individuals with elevated ALT levels has been shown to characterize more severe FLD. Thus, aim of the study was to investigate the association between fetuin-A level and the coexistence of elevated ALT levels and metabolic syndrome (ALT-MetS). Methods: A population-based cross-sectional study including 728 individuals (age 50-77 years) was conducted. We used multivariable logistic regression analysis to assess the association between serum fetuin-A level and the dichotomous outcome ALT-MetS, defined as coexistence of elevated ALT level (>75th percentile) and metabolic syndrome (any three of the components: abdominal obesity, elevated triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, abnormal glucose metabolism). Results: Individuals with a high fetuin-A level had an odds ratio (OR) for ALT-MetS of 2.22 [95% confidence interval (CI) 1.36-3.63; Ptrend=<0.001] comparing extreme tertiles. After excluding individuals with cancer, stroke, or myocardial infarction, individuals with high fetuin-A levels had an OR for ALT-MetS of 2.48 (95% CI 1.38-4.47) comparing extreme tertiles, and we observed statistical interaction between fetuin-A level and age (P=0.048). Fetuin-A level was associated with ALT-MetS in young individuals, defined as <64 years of age (OR 3.30, 95% CI 1.45-7.55; Ptrend=0.004), and not statistically significant in older individuals (OR 1.79, 95% CI 0.74-4.31; Ptrend=0.197). Conclusions: Fetuin-A level was positively associated with ALT-MetS, particularly in younger individuals. Prospective studies in larger populations are warranted.
    No preview · Article · Aug 2013 · Metabolic syndrome and related disorders
Show more